Alexandria Forbes, Ph.D., president and chief executive officer, will be participating on two panel discussions:

In Vivo Gene Therapy for Ocular Diseases: Regulatory Flexibility, Endpoints & Biomarkers
Tuesday at 8:45 a.m. ET

Gene Therapy for neurodegenerative diseases – are we there yet?
Tuesday at 3:30 p.m. ET

Retina Subspecialty Day 2 (for registered attendees)
Section X: Late Breaking Developments, Part II
Oral Presentation

Abstract Title: Ph1/2 AAV5-RPGR (Botaretigene Sparoparvovec) Gene Therapy Trial in RPGR-associated X-linked Retinitis Pigmentosa (XLRP)

Presenter: Dr. Michel Michaelides, Professor of Ophthalmology, UCL Institute of Ophthalmology in Dept. of Genetics